RxDoctor Payments Data

Jay Mellen, MD

Gastroenterology · Scottsdale, AZNPI 1609871979

Payments from drug & device makers

$3,261in general payments, 2019–2025

Across 78 payments — averaging $41.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$552
  • Madrigal Pharmaceuticals$287
  • Regeneron Healthcare Solutions, Inc.$127
  • Intercept Pharmaceuticals, Inc.$113
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$52
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$3,23899%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,261 in reported general payments places this provider in the 40th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$32,869
Medicare patients
180
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab11$88,637
XifaxanRifaximin25$85,660
LinzessLinaclotide19$19,724
Mesalamine20$9,142
Adefovir Dipivoxil11$5,626
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates57$3,771
Pantoprazole Sodium291$3,629
Mercaptopurine17$1,273
Dicyclomine Hcl36$1,117
Balsalazide Disodium13$772
Omeprazole42$634
Sucralfate23$587
Ondansetron OdtOndansetron37$513
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl24$379
LoperamideLoperamide Hcl12$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$52$85,66025 claims
AbbVieLinzess$2,076$19,72419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →